(3S,4R)-4-phenyltetrahydrofuran-3-ol | 130871-09-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3S,4R)-4-phenyltetrahydrofuran-3-ol
• 英文别名: trans-4-phenyltetrahydrofuran-3-ol；Rac-(3r,4s)-4-phenyloxolan-3-ol；(3S,4R)-4-phenyloxolan-3-ol
• CAS: 130871-09-9
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: DMERZAYEXRFPAW-VHSXEESVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3S,4R)-4-phenyltetrahydrofuran-3-ol 在 水 、 三苯基膦 、 sodium hydroxide 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 8.0h， 生成 2-(trans-4-phenyltetrahydrofuran-3-yl)isoindoline-1,3-dione
  参考文献：
  名称：

  [EN] PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS
  [FR] COMPOSÉS PYRAZOLO HÉTÉROCYCLIQUES CONDENSÉS COMME INHIBITEURS D'ERK

  摘要：

  本公开提供了一种化合物，其化学式为（I），或其在药学上可接受的盐，可作为Erk抑制剂。它们在治疗通过抑制Erk可治疗的疾病中具有潜在用途，如癌症。本公开还提供了一种药物组合物，包括化学式I的化合物和/或其在药学上可接受的盐以及药学上可接受的载体。

  公开号：

  WO2017028314A1
• 作为产物：
  描述：

  [(3S,4R)-4-phenyloxolan-3-yl] acetate 生成 (3S,4R)-4-phenyltetrahydrofuran-3-ol
  参考文献：
  名称：

  SEEMAYER, ROBERT;SCHNEIDER, MANFRED P., J. CHEM. SOC. PERKIN TRANS. PT 1,(1990) N, C. 2359-2360

  摘要：

  DOI：

文献信息

• Enantioselective Cross-Coupling of <i>meso</i>-Epoxides with Aryl Halides
  作者：Yang Zhao、Daniel J. Weix

  DOI：10.1021/jacs.5b01909

  日期：2015.3.11

  The first enantioselective cross-electrophile coupling of aryl bromides with meso-epoxides to form trans-β-arylcycloalkanols is presented. The reaction is catalyzed by a combination of (bpy)NiCl2 and a chiral titanocene under reducing conditions. Yields range from 57 to 99% with 78–95% enantiomeric excess. The 30 examples include a variety of functional groups (ether, ester, ketone, nitrile, ketal

  首次提出了芳基溴化物与内消旋环氧化物形成反式-β-芳基环烷醇的对映选择性交叉亲电偶联。该反应由(bpy)NiCl 2 和手性二茂钛在还原条件下的组合催化。产率范围为 57% 至 99%，对映体过量为 78-95%。这 30 个例子包括各种官能团（醚、酯、酮、腈、缩酮、三氟甲基、磺酰胺、磺酸酯）、芳基和乙烯基卤化物以及五至七元环。一氧化环辛烯向芳基[3.3.0]双环辛醇的转化强烈暗示了碳自由基的中介作用。
• Highly Enantioselective Organocatalytic Oxidative Kinetic Resolution of Secondary Alcohols Using Chiral Alkoxyamines as Precatalysts: Catalyst Structure, Active Species, and Substrate Scope
  作者：Keiichi Murakami、Yusuke Sasano、Masaki Tomizawa、Masatoshi Shibuya、Eunsang Kwon、Yoshiharu Iwabuchi

  DOI：10.1021/ja509766f

  日期：2014.12.17

  The development and characterization of enantioselective organocatalytic oxidative kinetic resolution (OKR) of racemic secondary alcohols using chiral alkoxyamines as precatalysts are described. A number of chiral alkoxyamines have been synthesized, and their structure-enantioselectivity correlation study in OKR has led us to identify a promising precatalyst, namely, 7-benzyl-3-n-butyl-4-oxa-5-azahomoadamantane

  描述了使用手性烷氧基胺作为预催化剂的外消旋仲醇的对映选择性有机催化氧化动力学拆分 (OKR) 的开发和表征。已经合成了许多手性烷氧基胺，它们在 OKR 中的结构-对映选择性相关性研究使我们确定了一种有前途的前催化剂，即 7-苄基-3-正丁基-4-氧杂-5-氮杂高金刚烷，它提供了各种手性脂肪族仲醇（ee 高达 >99%，k(rel) 高达 296）。在一项机理研究中，含氯氧铵物种被确定为烷氧基胺预催化剂原位生成的活性物种，并且发现氯原子对于高反应性和对映选择性至关重要。
• [EN] 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZOLO[4,3-A]PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2012062750A1

  公开（公告）日：2012-05-18

  The present invention relates to novel triazolo [4,3-a]pyridine derivatives of Formula (I), wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及式(I)的新三唑[4,3-a]吡啶衍生物，其中所有基团均如权利要求中所定义。根据发明的化合物是代谢型谷氨酸受体2型("mGluR2")的正变构调节剂，用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及mGluR2亚型的代谢型受体的疾病。本发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病。
• 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA
  申请人：Thewlis Kevin Michael

  公开号：US20090221643A1

  公开（公告）日：2009-09-03

  Compounds of formula (I), salts and solvates thereof are provided: wherein Ar is selected from phenyl, pyridyl and thienyl optionally substituted with one or more groups Y; and each Y group is independently selected from the group consisting of: halo, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, cyano, C(O)C 1-4 alkyl, NHSO 2 C 1-4 alkyl, NMeSO 2 C 1-4 alkyl, NHCOC 1-4 alkyl, NMeCOC 1-4 alkyl, SOC 1-4 alkyl, SO 2 C 1-4 alkyl and CO 2 C 1-4 alkyl, or two Y groups together form a cyclic group —O(CH 2 )O—. Processes for preparation, and uses thereof in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.

  提供式(I)的化合物、盐和溶剂化物，其中Ar从苯基、吡啶基和噻吩基中选择，可选地用一个或多个Y基团取代；每个Y基团独立地从以下基团中选择：卤、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、氰基、C（O）C1-4烷基、NHSO2C1-4烷基、NMeSO2C1-4烷基、NHCOC1-4烷基、NMeCOC1-4烷基、SOC1-4烷基、SO2C1-4烷基和CO2C1-4烷基，或两个Y基团共同形成一个环状基团- O（CH2）O-。还公开了制备过程以及在治疗由谷氨酸受体功能降低或不平衡介导的疾病或病症，例如精神分裂症或认知障碍中的用途。
• 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Cid-Núñez José Maria

  公开号：US20130338185A1

  公开（公告）日：2013-12-19

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及一种新型的三唑并[4,3-a]吡啶衍生物，其化学式为（I），其中所有基团如权利要求中所定义。本发明的化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及mGluR2代谢型受体参与的疾病。本发明还涉及包含这种化合物的制药组合物，制备这种化合物和组合物的过程以及使用这种化合物预防或治疗mGluR2参与的神经和精神障碍和疾病。